# Safety Summary Variant 1 works as expected

    Code
      res
    Output
                                                                    Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                     (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                37 (43.0%)        61 (84.7%)            64 (66.7%)     
      Total number of AEs                                              75               197                    181        
      Total number of deaths                                        2 (2.3%)             0                  1 (1.0%)      
      Total number of patients withdrawn from study due to an AE   9 (10.5%)          5 (6.9%)             10 (10.4%)     
      Total number of patients with at least one                                                                          
        AE with fatal outcome                                       2 (2.3%)          2 (2.8%)              2 (2.1%)      
        Serious AE                                                     0                 0                      0         
        Serious AE leading to withdrawal from treatment                0                 0                      0         
        Serious AE leading to dose modification/interruption           0                 0                      0         
        Related Serious AE                                             0                 0                      0         
        AE leading to withdrawal from treatment                     6 (7.0%)         10 (13.9%)            10 (10.4%)     
        AE leading to dose modification/interruption               16 (18.6%)        35 (48.6%)            34 (35.4%)     
        Related AE                                                     0                 0                      0         
        Related AE leading to withdrawal from treatment                0                 0                      0         
        Related AE leading to dose modification/interruption           0                 0                      0         
        Severe AE (at greatest intensity)                           2 (2.3%)          2 (2.8%)              8 (8.3%)      

# Safety Summary Variant 2 (with Medical Concepts Section) works as expected

    Code
      res
    Output
                                                                    Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                     (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                37 (43.0%)        61 (84.7%)            64 (66.7%)     
      Total number of AEs                                              75               197                    181        
      Total number of deaths                                        2 (2.3%)             0                  1 (1.0%)      
      Total number of patients withdrawn from study due to an AE   9 (10.5%)          5 (6.9%)             10 (10.4%)     
      Total number of patients with at least one                                                                          
        AE with fatal outcome                                       2 (2.3%)          2 (2.8%)              2 (2.1%)      
        Serious AE                                                     0                 0                      0         
        Serious AE leading to withdrawal from treatment                0                 0                      0         
        Serious AE leading to dose modification/interruption           0                 0                      0         
        Related Serious AE                                             0                 0                      0         
        AE leading to withdrawal from treatment                     6 (7.0%)         10 (13.9%)            10 (10.4%)     
        AE leading to dose modification/interruption               16 (18.6%)        35 (48.6%)            34 (35.4%)     
        Related AE                                                     0                 0                      0         
        Related AE leading to withdrawal from treatment                0                 0                      0         
        Related AE leading to dose modification/interruption           0                 0                      0         
        Grade 3-5 AE                                                8 (9.3%)         14 (19.4%)            16 (16.7%)     
      Total number of patients with at least one                                                                          
        SMQ01 (BROAD)                                               4 (4.7%)         10 (13.9%)             6 (6.2%)      
        SMQ02 (NARROW)                                              3 (3.5%)          5 (6.9%)              6 (6.2%)      
        CQ01                                                        7 (8.1%)          6 (8.3%)              3 (3.1%)      

# Safety Summary Variant 3 (with Modified Rows) works as expected

    Code
      res
    Output
                                                                    Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                     (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                37 (43.0%)        61 (84.7%)            64 (66.7%)     
      Total number of AEs                                              75               197                    181        
      Total number of deaths                                        2 (2.3%)             0                  1 (1.0%)      
      Total number of patients withdrawn from study due to an AE   9 (10.5%)          5 (6.9%)             10 (10.4%)     
      Total number of patients withdrawn informed consent              0                 0                      0         
      Total number of patients with at least one                                                                          
        AE with fatal outcome                                       2 (2.3%)          2 (2.8%)              2 (2.1%)      
        Serious AE                                                     0                 0                      0         
        AE leading to withdrawal from treatment                     6 (7.0%)         10 (13.9%)            10 (10.4%)     
        Related AE                                                     0                 0                      0         
        Grade 3-5 AE                                                8 (9.3%)         14 (19.4%)            16 (16.7%)     
        Grade 4/5 AE                                                6 (7.0%)          7 (9.7%)             11 (11.5%)     

# Safety Summary Variant 4 (with Rows Counting Events and Additional Sections) works as expected

    Code
      res
    Output
                                                                    Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                     (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                37 (43.0%)        61 (84.7%)            64 (66.7%)     
      Total number of AEs                                              75               197                    181        
      Total number of deaths                                        2 (2.3%)             0                  1 (1.0%)      
      Total number of patients withdrawn from study due to an AE   9 (10.5%)          5 (6.9%)             10 (10.4%)     
      Total number of patients with at least one                                                                          
        AE with fatal outcome                                       2 (2.3%)          2 (2.8%)              2 (2.1%)      
        Serious AE                                                     0                 0                      0         
        AE leading to withdrawal from treatment                     6 (7.0%)         10 (13.9%)            10 (10.4%)     
        AE leading to dose modification/interruption               16 (18.6%)        35 (48.6%)            34 (35.4%)     
        Related AE                                                     0                 0                      0         
        Grade 3-5 AE                                                8 (9.3%)         14 (19.4%)            16 (16.7%)     
      Total number of unique preferred terms which are                                                                    
        Serious AE                                                     0                 0                      0         
        AE leading to dose modification/interruption                   9                 10                    10         
        Related AE                                                     0                 0                      0         
        Grade 3-5 AE                                                   7                 7                      8         
        Grade 4/5 AE                                                   4                 4                      8         
      Total number of adverse events which are                                                                            
        Serious AE                                                     0                 0                      0         
        AE leading to dose modification/interruption                   21                52                    48         
        Related AE                                                     0                 0                      0         
        Grade 3-5 AE                                                   11                16                    19         
        Grade 4/5 AE                                                   7                 7                     11         

